Treatment.com AI Inc. to Rebrand as Rocket Doctor AI Inc., Aligning Business with Evolving Product Portfolio and Market Strategy
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has announced its rebranding to Rocket Doctor AI Inc., with trading under the new ticker symbol AIDR beginning August 21, 2025. This strategic transformation follows the successful April 2025 acquisition of Rocket Doctor Inc.
The rebranding unifies the company's proprietary Global Library of Medicine (GLM) with Rocket Doctor's digital health platform, creating an integrated solution that leverages AI, large language models, and connected medical devices to improve healthcare access. The combined technology stack focuses on delivering AI-enhanced clinical and diagnostic tools, particularly targeting rural, remote, and underserved communities across North America.
The company's GLM platform has undergone over 10,000 expert medical reviews and aims to reduce administrative burden for healthcare professionals while improving patient care quality and consistency.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) ha annunciato il rebranding in Rocket Doctor AI Inc., con le azioni che inizieranno a trattare con il nuovo ticker AIDR a partire dal 21 agosto 2025. Questa trasformazione strategica segue l’acquisizione di Rocket Doctor Inc. completata nell’aprile 2025.
Il rebranding integra la proprietaria Global Library of Medicine (GLM) dell’azienda con la piattaforma di salute digitale di Rocket Doctor, dando vita a una soluzione unificata che sfrutta l’intelligenza artificiale, i modelli linguistici di larga scala e dispositivi medici connessi per migliorare l’accesso alle cure. Lo stack tecnologico combinato è orientato a fornire strumenti clinici e diagnostici potenziati dall’AI, con un focus particolare sulle comunità rurali, remote e svantaggiate del Nord America.
La piattaforma GLM dell’azienda ha già superato le 10.000 revisioni mediche effettuate da esperti e si propone di ridurre gli oneri amministrativi degli operatori sanitari migliorando al contempo la qualità e la coerenza dell’assistenza ai pazienti.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) ha anunciado su cambio de marca a Rocket Doctor AI Inc., y sus acciones comenzarán a cotizar con el nuevo símbolo AIDR a partir del 21 de agosto de 2025. Esta transformación estratégica sigue a la exitosa adquisición de Rocket Doctor Inc. en abril de 2025.
El rebranding unifica la propietaria Global Library of Medicine (GLM) de la compañía con la plataforma de salud digital de Rocket Doctor, creando una solución integrada que aprovecha la inteligencia artificial, los modelos de lenguaje a gran escala y dispositivos médicos conectados para mejorar el acceso a la atención sanitaria. La pila tecnológica combinada se centra en ofrecer herramientas clínicas y diagnósticas mejoradas con IA, con especial atención a comunidades rurales, remotas y desatendidas en Norteamérica.
La plataforma GLM de la compañía ha sido sometida a más de 10.000 revisiones médicas por expertos y pretende reducir la carga administrativa de los profesionales sanitarios mientras mejora la calidad y la coherencia del cuidado del paciente.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF)는 사명을 Rocket Doctor AI Inc.로 변경한다고 발표했으며, 새로운 티커 AIDR로의 거래는 2025년 8월 21일부터 시작됩니다. 이번 전략적 변화는 2025년 4월 Rocket Doctor Inc. 인수의 성공에 따른 것입니다.
이번 리브랜딩은 회사의 독점적 Global Library of Medicine (GLM)을 Rocket Doctor의 디지털 헬스 플랫폼과 통합하여, 인공지능(AI), 대규모 언어 모델, 연결된 의료 기기를 활용해 의료 접근성을 개선하는 통합 솔루션을 창출합니다. 결합된 기술 스택은 AI 기반의 임상·진단 도구 제공에 중점을 두며, 특히 북미의 농촌·외딴 지역 및 의료 취약 지역을 타겟으로 합니다.
회사 GLM 플랫폼은 이미 10,000건 이상의 전문가 의학 검토를 거쳤으며, 의료진의 행정 부담을 줄이고 환자 치료의 질과 일관성을 향상시키는 것을 목표로 합니다.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) a annoncé son renommage en Rocket Doctor AI Inc., les actions étant négociées sous le nouveau symbole AIDR à partir du 21 août 2025. Cette transformation stratégique fait suite à l’acquisition réussie de Rocket Doctor Inc. en avril 2025.
Le rebranding unifie la Global Library of Medicine (GLM) propriétaire de la société avec la plateforme de santé numérique de Rocket Doctor, créant une solution intégrée qui exploite l’IA, les grands modèles de langage et des dispositifs médicaux connectés pour améliorer l’accès aux soins. L’ensemble technologique combiné vise à fournir des outils cliniques et diagnostiques renforcés par l’IA, en ciblant notamment les communautés rurales, isolées et mal desservies en Amérique du Nord.
La plateforme GLM de la société a fait l’objet de plus de 10 000 revues médicales d’experts et entend réduire la charge administrative des professionnels de santé tout en améliorant la qualité et la cohérence des soins aux patients.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) hat seine Umbenennung in Rocket Doctor AI Inc. bekanntgegeben; der Handel unter dem neuen Tickersymbol AIDR beginnt am 21. August 2025. Diese strategische Neuausrichtung folgt auf die im April 2025 abgeschlossene Übernahme von Rocket Doctor Inc.
Das Rebranding vereint die proprietäre Global Library of Medicine (GLM) des Unternehmens mit der digitalen Gesundheitsplattform von Rocket Doctor und schafft eine integrierte Lösung, die KI, große Sprachmodelle und vernetzte medizinische Geräte nutzt, um den Zugang zur Gesundheitsversorgung zu verbessern. Der kombinierte Technologie-Stack konzentriert sich auf AI-gestützte klinische und diagnostische Werkzeuge, mit besonderem Fokus auf ländliche, abgelegene und unterversorgte Gemeinden in Nordamerika.
Die GLM-Plattform des Unternehmens hat bereits mehr als 10.000 fachliche medizinische Prüfungen durchlaufen und zielt darauf ab, die administrative Belastung für Gesundheitsfachkräfte zu verringern und gleichzeitig die Qualität und Konsistenz der Patientenversorgung zu verbessern.
- Strategic integration of GLM's AI technology with Rocket Doctor's established digital health platform
- Expanded market reach into underserved communities across North America
- Platform validated with over 10,000 expert medical reviews
- Enhanced service offering combining AI diagnostics with telemedicine capabilities
- Clear path to commercialization following successful April 2025 acquisition
- Potential integration challenges merging two distinct technology platforms
- Regulatory compliance requirements across multiple jurisdictions
- Competition in the growing AI healthcare and telemedicine markets
- New name to take effect and begin trading on the Canadian Securities Exchange under the new ticker AIDR effective August 21, 2025
- Rebrand unites the company’s proprietary Global Library of Medicine (GLM) with Rocket Doctor Inc’s leading digital health platform to deliver scalable, AI-enhanced clinical and diagnostic tools
- Leveraging large language models, connected medical devices, and proprietary software to improve healthcare access for rural, remote, and underserved communities across North America
- Builds on successful April 2025 acquisition of Rocket Doctor Inc., marking a pivotal step towards commercialization and delivering measurable value to patients, providers, and shareholders
VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that it is rebranding and reincorporating as Rocket Doctor AI Inc. This milestone reflects the Company’s continued evolution and its commitment to advancing its strategic vision.
Concurrently with the completion of the proposed name change, the Company’s trading symbol on the Canadian Securities Exchange will be changed from “TRUE” to “AIDR”. The new CUSIP number is 772924106 and the ISIN number is CA7729241066 for the Company’s common shares. The Company’s common shares will begin trading under the new ticker symbol on 21st August 2025.
The new name reflects the integration of the proprietary AI-driven Global Library of Medicine (GLM) with the recently acquired Rocket Doctor Inc. Rocket Doctor is a leading digital health platform and marketplace that empowers physicians to practice independently and deliver comprehensive care while connecting them to patients across North America. This includes rural and remote communities in Canada and patients on Medicaid and Medicare in the United States, leveraging large language models, bluetooth medical devices, and proprietary software.
The new stock symbol, AIDR, is intended to better represent the Company’s core focus on AI-driven administrative, diagnostic, clinical decision support and referral solutions that empower both healthcare professionals and patients.
This change follows the successful acquisition of Rocket Doctor Inc. in April 2025, which brought a strong complement to Treatment’s technology stack. Together, these accumulated assets position the Company to deliver scalable, AI-enhanced healthcare solutions at a time of growing demand for efficiency, accuracy, and improved care delivery.
Dr. Essam Hamza, CEO of Treatment.com AI Inc., comments: “We are very excited about this next chapter for the company. This name change marks a natural step in uniting our technology and service offerings under a single, stronger identity. Following the acquisition of Rocket Doctor, we are at an important inflection point. As we move toward the next phase of commercialization and prepare for our Q2 announcement, we remain focused on delivering practical; AI driven; clinically validated; scalable solutions and keeping our shareholders informed of our progress.”
Dr. William Cherniak, CEO of Rocket Doctor Inc., comments: “It’s been a fast-paced journey since joining the team at Treatment.com AI. We couldn’t be more thrilled to take the ethos and brand brought from our work across North America to now jointly power Rocket Doctor AI. There’s much more to go in our work of improving physicians’ practice of medicine, while in parallel increasing access to care for patients in need; this refined name makes clear our focus on technology as a critical component to achieving these objectives. Onward and upward!”
This strategic rebrand underscores the Company’s commitment to advancing accessible, AI-enhanced healthcare solutions and positions Rocket Doctor AI Inc. to deliver sustained value to patients, providers, and shareholders in the years ahead.
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment.com AI’s products and services: www.treatment.com or email: info@treatment.com
About Rocket Doctor Inc.
Rocket Doctor is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Its proprietary software and AI-powered tools enable providers to deliver high-quality comprehensive care remotely, with a focus on reaching underserved and remote communities across North America. By removing barriers to care and restoring physician autonomy, Rocket Doctor is redefining what modern healthcare looks like.
To learn more about Rocket Doctor’s platform and services, visit www.rocketdoctor.ca (Canada) www.rocketdoctor.io (U.S.), or contact media@rocketdoctor.io .
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
For media inquiries, contact: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Dr. Bill Cherniak, CEO, Rocket Doctor
Email: bill@rocketdoctor.io
Media inquiries: media@rocketdoctor.io
Cautionary Statements
This news release contains forward-looking statements that are based on Treatment’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
FAQ
When will Treatment.com AI (TREIF) begin trading as Rocket Doctor AI under the new ticker AIDR?
What is the strategic rationale behind Treatment.com AI's rebranding to Rocket Doctor AI?
How does Rocket Doctor AI's Global Library of Medicine (GLM) benefit healthcare providers?
What markets does Rocket Doctor AI serve after the merger?
When did Treatment.com AI acquire Rocket Doctor Inc.?
